Provectus Appoints Heather Raines, CPA as Chief Financial Officer
25 mars 2019 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 25, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the appointment of Heather Raines as the Company’s Chief Financial Officer (CFO). Mrs. Raines had previously...
Provectus Provides Update on Metastatic Uveal Melanoma Clinical Development Program for Investigational Drug PV-10
21 mars 2019 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 21, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updates on the Company's metastatic uveal melanoma drug development program for its lead investigational...
PROVECTUS ANNOUNCES GRANT OF ORPHAN DRUG DESIGNATION IN U.S. TO PV-10 FOR TREATMENT OF OCULAR MELANOMA
12 févr. 2019 07h30 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that orphan drug designation (ODD) status was granted by the U.S. Food and Drug Administration (FDA) to small...
PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON MELANOMA CLINICAL DEVELOPMENT PROGRAM FOR INVESTIGATIONAL DRUG PV-10
06 déc. 2018 08h30 HE
|
Provectus Biopharmaceuticals Inc.
Lesion-level response data from main cohort of advanced melanoma patients naïve to immune checkpoint inhibition in Phase 1b/2 combination study of PV-10 and KEYTRUDA® (pembrolizumab) presented at...
University of Tennessee Haslam College of Business Recognizes Provectus Biopharmaceuticals Chairman Ed Pershing as 2018 Outstanding Entrepreneur
12 nov. 2018 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that Ed Pershing, CPA, the Chairman of the Company’s board of directors, was recognized by the Haslam...
US FDA GRANTS PV-10 ORPHAN DRUG DESIGNATION FOR NEUROBLASTOMA
05 nov. 2018 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company was granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA)...
PROVECTUS BIOPHARMACEUTICALS EXPANDS PATENT PORTFOLIO WITH ADOPTIVE CELL TRANSFER-BASED USE OF INVESTIGATIONAL CANCER DRUG
18 sept. 2018 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed the Company’s patent application for...
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATIONS AT SMR 2018 CONGRESS
11 sept. 2018 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from two ongoing clinical trials, single agent PV-10 and PV-10 in combination with checkpoint...